Lipoprotein(a) Clinical Trials in Beijing, Beijing Municipality
2 recruitingBeijing, Beijing Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled618 locationsNCT07517263
Recruiting
Not Applicable
24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial
Coronary Artery DiseaseDrug-eluting StentDual Antiplatelet Therapy+1 more
China National Center for Cardiovascular Diseases3,300 enrolled1 locationNCT06014060